ipilimumab,nivolumab
bms
[]
29 month follow-up of cm648 in advanced escc (nivo+chemo vs chemo, nivo+ipi vs chemo). os, pfs benefit maintained, driven by the pdl1 &gt;1% population with nivo-chemo vs chemo. ipi/nivo also maintains os benefit but no pfs benefit vs chemo #gi23 
Fellow @PennCancer. @NIH_LRP.  @PC3Innovation. MSCE Student. GI Cancers. Former @UTSWIMchief. Lucas’ dad forever. Views own. ASCO FCOI https://t.co/rmHB23k0Ph